Know Cancer

or
forgot password

Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases A Case Matched Control Study


N/A
18 Years
90 Years
Not Enrolling
Both
Colorectal Liver Metastases

Thank you

Trial Information

Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases A Case Matched Control Study


Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor
(VEGF) increasingly added to other drugs in the treatment of colorectal cancer. Bev is
typically used in combination with other chemotherapeutic agents such as oxaliplatin,
irinotecan, leucovorin and 5-fluorouracil (5-FU) for treatment of patients with CRLM. The
objective of this study was to assess the impact of neoadjuvant bevacizumab on clinical
outcome after hepatectomy of colorectal liver metastases (CRLM).

Patients, who underwent liver resection due to colorectal liver metastases after neoadjuvant
chemotherapy, operated between 2005 and 2007 will be evaluated retrospectively. The patients
will be distributed in two groups, either with or without bevacicumab. Outcome parameters
are mortality, complications, hospital stay and ICU stay. To increase the power of the study
the total number of patients will be increased by adding patients from other centers.
Results will be adjusted for the propensity of developing complications.


Inclusion Criteria:



- Patients with neoadjuvant chemotherapy prior to liver resection

Exclusion Criteria:

- Patients without neoadjuvant chemotherapy

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Overall complications

Outcome Time Frame:

postoperative

Safety Issue:

Yes

Principal Investigator

Stefan Breitenstein, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Departement of Visceral and Transplantation Surgery of University hospital of Zurich

Authority:

Switzerland: Ethic committee of Kanton Zurich,

Study ID:

StV 12-2009

NCT ID:

NCT00875147

Start Date:

April 2009

Completion Date:

September 2009

Related Keywords:

  • Colorectal Liver Metastases
  • neoadjuvant chemotherapy
  • bevacizumab
  • Neoplasm Metastasis
  • Neoplasms, Second Primary
  • Liver Neoplasms

Name

Location